Email this article 
Invasive aspergillosis: results of multicenter study
- Authors: Klimko N.N.1, Shadrivova O.V.2, Khostelidi S.N.2, Desyatik E.A.2, Borzova Y.V.2, Chernopyatova R.M.2, Shagdileeva E.V.2, Volkova A.G.3, Popova M.O.3, Zyuzgin I.S.4, Ruzhinskaya O.S.4, Ryabykina O.Y.4, Medvedeva N.V.5, Kolbin A.S.6, Boychenko E.G.6, Bogomolova T.S.2, Ignatieva S.M.2, Zubarovskaya L.S.3, Afanasiev B.V.3
-
Affiliations:
- P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology
- P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
- Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
- Leningrad Regional Hospital, Saint Petersburg
- Municipal Hospital № 31, Saint Petersburg
- Children Municipal Hospital № 1, Saint Petersburg
- Issue: Vol 9, No 2 (2014)
- Pages: 13-19
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 17.09.2014
- URL: https://oncohematology.abvpress.ru/ongm/article/view/110
- DOI: https://doi.org/10.17650/1818-8346-2014-9-2-13-19
- ID: 110
Cite item
Full Text
Abstract
We present the results of a multicenter study of 445 patients with “proven” and “probable” invasive aspergillosis (EORTC/MSG, 2008). Invasive aspergillosis usually occurs in patients with hematological malignancies (88 %), main underlying diseases were acute myeloid and acute lymphoblastic leukemia. The risk factors: prolonged agranulocytosis (64 %), cytostatic chemotherapy (57 %), corticosteroid treatment (45 %), and allogeneic hematopoietic stem cells transplantation (29 %). The pathogens – A. fumigatus (42 %), A. niger (33 %), and A. flavus (21 %). The main site of infection were lungs (86 %). 12 week overall survival was 83 %. Bronchoscopy use for the early diagnosis (p = 0.01), adequate
therapy with voriconazole (p = 0.002) and secondary antifungal prophylaxis (p = 0.0003) were positive prognostic factors for survival of patients with invasive aspergillosis.
About the authors
N. N. Klimko
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology
Author for correspondence.
Email: n_klimko@mail.ru
Russian Federation
O. V. Shadrivova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
S. N. Khostelidi
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
E. A. Desyatik
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
Yu. V. Borzova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
R. M. Chernopyatova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
E. V. Shagdileeva
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
A. G. Volkova
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation
M. O. Popova
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation
I. S. Zyuzgin
Leningrad Regional Hospital, Saint PetersburgRussian Federation
O. S. Ruzhinskaya
Leningrad Regional Hospital, Saint PetersburgRussian Federation
O. Ye. Ryabykina
Leningrad Regional Hospital, Saint PetersburgRussian Federation
N. V. Medvedeva
Municipal Hospital № 31, Saint PetersburgRussian Federation
A. S. Kolbin
Children Municipal Hospital № 1, Saint PetersburgRussian Federation
E. G. Boychenko
Children Municipal Hospital № 1, Saint PetersburgRussian Federation
T. S. Bogomolova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
S. M. Ignatieva
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgRussian Federation
L. S. Zubarovskaya
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation
B. V. Afanasiev
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation
References
Supplementary files
